ArticleFrontiers in endocrinology2021
Head-to-Head Comparison of
Article in Frontiers in endocrinology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- PSMA-targeted PET imaging for brain metastases from non-prostatic solid tumors: a systematic review.Frontiers in oncology · 2025Pooled it
- A Case Report of Incidental Thyroid Cancer Metastasis Detected in a PSMA PET/CT Scan of a Prostate Cancer Patient: Predicting RAI-Refractoriness.World journal of nuclear medicine · 2026Article
- Prostate-specific membrane antigen in malignant brain tumors: vascular heterogeneity, imaging promise, and therapeutic challenges.Frontiers in oncology · 2026Review
- [Frontiers in endocrinology · 2025Article
- Imaging through PSMA-targeted PET in patients diagnosed with radioiodine-refractory thyroid cancer, a flash in the pan or a game changer?Endocrine · 2024Article
- Prostate Specific Membrane Antigen Expression in a Syngeneic Breast Cancer Mouse Model.Molecular imaging and biology · 2024Article
- Prostate-Specific Membrane Antigen Radioligand Therapy in Non-Prostate Cancers: Where Do We Stand?Bioengineering (Basel, Switzerland) · 2024Review
- Prostate-Specific Membrane Antigen Positron Emission Tomography Oncological Applications beyond Prostate Cancer in Comparison to Other Radiopharmaceuticals.Diagnostics (Basel, Switzerland) · 2024Review
- Current clinical application of lutetium‑177 in solid tumors (Review).Experimental and therapeutic medicine · 2024Review
- Advances in the Development of Positron Emission Tomography Tracers for Improved Detection of Differentiated Thyroid Cancer.Cancers · 2024Review
- The complementary role of PSMA expression and [EJNMMI research · 2023Article
- Potential Role of PSMA-Targeted PET in Thyroid Malignant Disease: A Systematic Review.Diagnostics (Basel, Switzerland) · 2023Review
- Prostate-specific membrane antigen expression predicts recurrence of papillary thyroid carcinoma after total thyroidectomy.BMC cancer · 2022Review
- PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?Journal of clinical medicine · 2022Review
- PSMA Radioligand Uptake as a Biomarker of Neoangiogenesis in Solid Tumours: Diagnostic or Theragnostic Factor?Cancers · 2022Review
- Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer.Molecules (Basel, Switzerland) · 2022Review
- Personalized Diagnosis in Differentiated Thyroid Cancers by Molecular and Functional Imaging Biomarkers: Present and Future.Diagnostics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thyroid cancer is the main endocrine neoplasia worldwide, for which Methods: We retrospectively evaluated well differentiated metastatic thyroid cancer patients, who underwent a post therapeutic Results: Ten patients with differentiated thyroid cancer were included, of whom 80% were women and 20% men, mean age was 58 years old (± 11.6). Sixty-four metastatic lesions were analyzed, 67.19% had papillary histology and 32.81% were follicular type, the most affected site of metastases was bone in 57.81%, followed by lung 17.19%, lymph nodes 7.81%, postoperative thyroid bed 4.69%, brain 4.69% and others 7.81%. Conclusions:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.